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Definition and Basic Information
Mantle cell lymphoma belongs to the indolent lymphomas, despite its aggressive clinical course in most patients.
Clinical Presentation
The clinical picture is characterized by lymph-node enlargements and splenomegaly. Bonemarrow infiltration occurs in approx. 80-90% of the cases, lymphoma cells are detected in the blood in 20-30% of all patients. Extranodal manifestations (e.g. involvement of the GI tract, meningeosis lymphomatosa) occur more frequently than in follicular lymphomas [1] .
Diagnostics
Diagnosis is based on the histological examination of a suspicious lymph node. Immunohisto chemical staining for cyclinD1 overexpression and/or fluorescence in-situ hybridization (FISH) for t(11;14) are mandatory in order to differentiate this lymphoma from other lymphoma subtypes. As the therapy of indolent lymphomas depends on the stage of disease thorough diagnostics are essential prior to onset of therapy (staging). Positron emission tomography (PET) has no therapeutic consequences and is not recom mended.
• • •
In order to identify patients with an increased risk for acute and/or late complications, tests of lung function, the heart (ECG, cardiac echo) and renal function are absolutely necessary prior to the onset of therapy.
Staging
Staging is done by differentiating stages I to IV according to the Ann Arbor Classification, see Table 1 . However, the stage will be advanced in most cases due to the frequent bone marrow involvement. 
Therapy
Patients with indolent lymphomas should be treated, whenever possible, in clinical trials. A therapy algorithm is shown in Figure 1 . 
First-Line Therapy
Patients ≤ 65 years
In younger patients (≤65 years) a dose-intensified concept (induction plus high-dose consolida tion with autologous stem-cell transplantation, or HyperCVAD) is the standard therapy. It leads to a significant prolongation of progression-free and overall survival [6] . A cytarabine-contain ing regimen additionally increases progression-free survival [7] .
Patients > 65 years
Combination regimens for 'elderly patients' are R-CHOP, R-Bendamustine (cf. Appendix Systemic Therapy -Protocols), and R-FC especially in exclusively leukemic cases. However, the majority of patients will relapse within the first three years due to the aggressive course of the disease [8] . Maintenance therapy with rituximab after R-CHOP leads to a significant prolonga tion of remission duration and overall survival [9].
Indolent Course
In individual cases a watch & wait strategy with continuous monitoring in short intervals may be pursued if an indolent clinical course is suspected. Treatment in these patients is initiated upon progression of the lymphoma [5].
Relapse
Immunochemotherapy is the standard therapy in patients with late relapse (remission duration ≥ 6 months). Choice of the second line regime depends on the first line therapy.
In later relapses the mTOR inhibitor temsirolimus is superior to mono-chemotherapy, see Appendix Systemic Therapy -Protocols [10] .
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Other promising agents are proteasome inhibitors (bortezomib) and immunomodulatory substances (thalidomide, lenalidomide). However, no randomized studies are available [11, 12] .
Consolidation / Maintenance
Unless autologous transplantation has already been performed in first line treatment, it should be discussed at the time of the first relapse.
In case of a relapse after high-dose therapy an allogenic transplantation with reduced conditioning may be discussed for younger patients [1] .
Maintenance therapy with rituximab lead to a significant prolongation of progression-free survival in a small randomized study and can be applied individually.
Radioimmunotherapy may be an alternative option for consolidation. 
Monitoring and Follow-Up
